Literature DB >> 20824324

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Thierry Petit1, Marc Wilt, Michel Velten, Jean-François Rodier, Jean-Pierre Fricker, Patrick Dufour, Jean-Pierre Ghnassia.   

Abstract

Absence of hormonal receptors (HR) expression is a predictive factor of high pathologic complete response (pCR) rate after neo-adjuvant chemotherapy. However, HR-positive tumors are less chemosensitive. In the present study, we evaluated the predictive value of estrogen (ER) and progesterone (PgR) semi-quantitative expression in patients with HR-positive tumors treated uniformly with antracycline-based neoadjuvant chemotherapy without hormonal treatment. Value of HR expression as a predictive factor was then evaluated in a multivariate analysis with tumor grade, Ki67 index and HER2 expression. From January 2000 and December 2006, 177 patients with HR-positive breast ductal invasive carcinoma ≥2 cm in its largest diameter were treated with six cycles of an anthracycline-based neo-adjuvant chemotherapy. Tumor grade, ER, PgR, HER2 status and Ki67 index were determined on microbiopsy performed before chemotherapy. A semi-quantitative evaluation of ER and PgR expression by IHC was performed using the Barnes'score. pCR rate was significantly different (P < 0.001) according to the ER expression score. pCR rate was 28% for low score, 9% for medium score and 3% for high score. On the contrary, pCR rate was not significantly different (P = 0.49) according to the PgR expression score. In the multivariate analysis, ER expression score (P = 0.0002) and Ki67 index (P = 0.02) were the only predictive factors of response for HR-positive tumors. pCR after anthracycline-based chemotherapy is significantly correlated with the ER expression score.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824324     DOI: 10.1007/s10549-010-1142-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Microcalcification of Tumor is a Predictor of Response to Neoadjuvant Chemotherapy for Invasive Breast Carcinoma.

Authors:  Aya Murata; Naoko Sannomiya; Naoki Miyamoto; Naoyuki Ueda; Akira Kamida; Yuki Koyanagi; Haruki Nagira; Eriko Matsuda; Yuki Hashimoto; Kengo Sato; Yumi Hirooka; Keiko Hosoya; Yuzo Takagi; Yuko Tanaka; Kunio Araki; Kiyosuke Ishiguro; Yasuaki Hirooka
Journal:  Yonago Acta Med       Date:  2015-08-18       Impact factor: 1.641

2.  The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.

Authors:  Zhinong Jiang; Junlan Guo; Jianguo Shen; Mei Jin; Shuduo Xie; Linbo Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-05-03

3.  Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.

Authors:  G H Bain; E Collie-Duguid; G I Murray; F J Gilbert; A Denison; F McKiddie; T Ahearn; I Fleming; J Leeds; P Phull; K Park; S Nanthakumaran; K M Matula; H I Grabsch; P Tan; A Welch; L Schweiger; A Dahle-Smith; G Urquhart; M Finegan; R D Petty
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

Review 4.  Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.

Authors:  Miaomiao Tao; Shu Chen; Xianquan Zhang; Qi Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.